STAT published a Health Tech newsletter item headlined “The EPIC investigation, and a Teladoc surprise.” The publicly viewable page provides a headline, byline, image, and subscription prompts. It points readers to a subscriber-only article on Epic and a separate item involving Teladoc, but the public copy does not reproduce the investigation’s evidence or the specifics of Teladoc’s development.
The headline is direct. The reporting that would substantiate claims is not present on the free page. Readers encounter an explicit paywall message: the remainder of the story is reserved for STAT+ subscribers. That message is the main substantive element available to non-subscribers.
Mario Aguilar is listed as the author of the piece, with an Oct. 29, 2026 date stamp. Aguilar’s beat is described on the page: he covers technology in health care, FDA oversight of artificial intelligence, how Medicare pays for health tech, mental health chatbots, and wearables. His contact details — including an email address and social links — are provided on the public page.
The page also links to STAT’s Health Tech newsletter signup and to related STAT reporting. Those links contextualize the item within the outlet’s broader coverage of digital health and regulatory questions, but they do not replace the substantive subscriber material.
The visible content signals two distinct storylines: an investigation into Epic and a separate “surprise” related to Teladoc. A prominent image associated with Teladoc appears on the page. Beyond that, the public copy does not disclose investigative findings, company statements, regulatory filings, or data that would allow independent verification of any claims.
No methodological details were provided for the Epic investigation on the free page. The source did not describe the scope of the probe, the parties involved in the inquiry, or any evidence chain. Similarly, the source did not report what the Teladoc “surprise” entailed — there are no performance metrics, deal terms, clinical data, pricing changes, or regulatory actions included in the publicly available material.
The public page includes an editorial announcement: STAT will host a session at the HLTH conference in Las Vegas on the morning of Wednesday, Nov. 18. That item appears as an editorial event note on the page and is separate from the subscriber story. The page also promotes STAT+ access and lists subscription pricing tiers and plan options — a clear signal that deeper content is gated.
Navigation elements and related-article links appear throughout the page. The site surface lists other recent STAT pieces about Epic’s market position and health tech regulatory developments, offering readers avenues for contextual reading but not the investigative evidence from this specific story.
The publicly accessible portion of the article omits the core investigative material. The source did not report:
Those absences are explicit: the page repeatedly points readers to STAT+ for the remainder of the story. Because the source withheld those details on the public page, they cannot be restated or summarized here.
What precisely did investigators find about Epic? The public page does not say. Who spoke on the record about the Epic matter? The source did not report names or quotes in the free copy. What was the nature of the Teladoc “surprise”? The public material provides no description of the event, outcome, or evidence.
Readers who require the investigative details, direct quotes, or documentary evidence must consult the subscriber-only STAT+ article. For journalists and clinicians watching health-technology markets, the public page functions as a pointer rather than as a primary account. The next concrete steps to resolve the open questions are also not provided on the free page: there is no schedule of expected follow-up reporting, no links to filings, and no timeline for public release of documents.
Limitations: this rewrite is strictly bounded by the publicly available STAT page. The source did not include investigational results, trial data, corporate communications, or regulatory filings in the free copy. Any further factual claims would require access to the gated STAT+ report or to primary-source documents that the public page did not publish.